source
- Novartis stops ALS TREM2 stabilizer after Phase 2 miss, marking fourth trial setback in a monthNovartis has halted development of its TREM2 stabilizer VHB937, also known as lifonebart, for amyotrophic lateral sclerosis after the drug failed to meet either the primary or secondary endpoints i…
- Experts assess EU medical device and diagnostic regulations at RAPS Convergence 2026A panel of experts representing the European Commission, industry groups and notified bodies gathered in Charlotte, North Carolina during RAPS Convergence 2026. The group reviewed the current stat…